X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DIVIS LABORATORIES - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DIVIS LABORATORIES SUN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 26.3 31.2 84.1% View Chart
P/BV x 3.8 5.4 70.9% View Chart
Dividend Yield % 0.6 0.9 65.4%  

Financials

 SUN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
DIVIS LABORATORIES
Mar-17
SUN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8421,222 68.9%   
Low Rs572784 73.0%   
Sales per share (Unadj.) Rs131.6153.1 86.0%  
Earnings per share (Unadj.) Rs32.739.9 81.9%  
Cash flow per share (Unadj.) Rs38.044.6 85.2%  
Dividends per share (Unadj.) Rs3.5010.00 35.0%  
Dividend yield (eoy) %0.51.0 49.6%  
Book value per share (Unadj.) Rs152.7201.8 75.7%  
Shares outstanding (eoy) m2,399.26265.47 903.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.46.6 82.0%   
Avg P/E ratio x21.625.1 86.1%  
P/CF ratio (eoy) x18.622.5 82.8%  
Price / Book Value ratio x4.65.0 93.2%  
Dividend payout %10.725.0 42.8%   
Avg Mkt Cap Rs m1,696,877266,266 637.3%   
No. of employees `00017.59.7 179.9%   
Total wages/salary Rs m49,0234,687 1,045.8%   
Avg. sales/employee Rs Th18,028.34,175.0 431.8%   
Avg. wages/employee Rs Th2,798.8481.5 581.3%   
Avg. net profit/employee Rs Th4,479.51,089.3 411.2%   
INCOME DATA
Net Sales Rs m315,78440,643 777.0%  
Other income Rs m6,232749 832.1%   
Total revenues Rs m322,01641,392 778.0%   
Gross profit Rs m100,89314,460 697.7%  
Depreciation Rs m12,6481,233 1,025.5%   
Interest Rs m3,99823 17,690.3%   
Profit before tax Rs m90,47913,953 648.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,1163,349 361.8%   
Profit after tax Rs m78,46210,604 739.9%  
Gross profit margin %31.935.6 89.8%  
Effective tax rate %13.424.0 55.8%   
Net profit margin %24.826.1 95.2%  
BALANCE SHEET DATA
Current assets Rs m329,53740,105 821.7%   
Current liabilities Rs m178,8706,595 2,712.4%   
Net working cap to sales %47.782.5 57.9%  
Current ratio x1.86.1 30.3%  
Inventory Days Days79119 66.6%  
Debtors Days Days8381 103.2%  
Net fixed assets Rs m204,76619,995 1,024.1%   
Share capital Rs m2,399531 451.9%   
"Free" reserves Rs m363,99753,043 686.2%   
Net worth Rs m366,39753,574 683.9%   
Long term debt Rs m14,3610-   
Total assets Rs m614,10261,585 997.2%  
Interest coverage x23.6618.4 3.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.7 77.9%   
Return on assets %13.417.3 77.8%  
Return on equity %21.419.8 108.2%  
Return on capital %24.826.1 95.2%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m44,11835,384 124.7%   
Fx outflow Rs m24,48410,399 235.5%   
Net fx Rs m19,63424,985 78.6%   
CASH FLOW
From Operations Rs m70,82211,493 616.2%  
From Investments Rs m-42,216-11,372 371.2%  
From Financial Activity Rs m-22,854-93 24,547.7%  
Net Cashflow Rs m6,10728 21,502.5%  

Share Holding

Indian Promoters % 63.7 52.0 122.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 11.8 43.5%  
FIIs % 23.0 19.0 121.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 17.2 48.3%  
Shareholders   133,026 31,796 418.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Flat; Metal Stocks Witness Selling(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.23% while the Hang Seng is down 0.49%. The Nikkei 225 is trading down by 0.55%.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jan 24, 2018 11:27 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - FDC LTD. COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS